Ryan J. Watts sold $1.1M of DNLI
President and CEO at Denali Therapeutics Inc.. 40,000 shares at an average of $27.69, traded Oct 18, 2024, filed Oct 22, 2024.
Score components
- +25RoleCEO
- +25Trade size$1.1M at market
- +5Share of holdings soldSold 15% of holdings
- +8Cluster2 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m -7.9%, 3m -12.4%, 6m -44.5%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001714899-24-000206, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Oct 18, 2024 | MOption exercise Common Stock10b5-1 | +40,000 | $0.68 | $27k | 275,807 | Oct 22, 2024 |
| Oct 18, 2024 | SOpen-market sale Common Stock10b5-1 | -40,000 | $27.69 | $1.1M | 235,807 | Oct 22, 2024 |
| Oct 18, 2024 | MOption exercise Stock Option (right to buy)derivative10b5-1 | -40,000 | $0.00 | $0 | 1,078,091 | Oct 22, 2024 |
Related signals
Other insiders at Denali Therapeutics Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 36Weak | Denali Therapeutics Inc. | Peter Scott Chin Chief Medical Officer | $37k 1,654 shares | -1% | |
| 33Weak | Denali Therapeutics Inc. | Nancy Thornberry director | $262k 11,439 shares | -37% | |
| 18Weak | Denali Therapeutics Inc. | Alexander O. Schuth COFO and Secretary | $65k 2,768 shares | -1% | |
| 43Moderate | Denali Therapeutics Inc. | Steve E. Krognes director | $69k 3,339 shares | -11% | |
| 67Notable | Denali Therapeutics Inc. | Ryan J. Watts President and CEO | $751k 36,916 shares | -13% | |
| 44Moderate | Denali Therapeutics Inc. | Alexander O. Schuth COFO and Secretary | $308k 15,162 shares | -6% | |
| 44Moderate | Denali Therapeutics Inc. | Carole Ho Chief Medical Officer | $308k 15,162 shares | -8% | |
| 18Weak | Denali Therapeutics Inc. | Vicki L Sato director | $64k 3,080 shares | -3% | |
| 50Moderate | Denali Therapeutics Inc. | Steve E. Krognes director | $608k 30,000 shares | -51% | |
| 40Moderate | Denali Therapeutics Inc. | David P Schenkein director | $1.9M 59,441 shares | -87% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.